1. Search Result
Search Result
Results for "

glycogen

" in MedChemExpress (MCE) Product Catalog:

73

Inhibitors & Agonists

6

Biochemical Assay Reagents

18

Peptides

1

Inhibitory Antibodies

7

Natural
Products

6

Recombinant Proteins

5

Antibodies

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-113511

    Endogenous Metabolite Bacterial Metabolic Disease
    Glycogen is a glycolytic intermediates and high-energy phosphates that can serve as a form of energy storage in humans, animals, fungi, and bacteria.
    Glycogen, Mussel
  • HY-113511A

    Endogenous Metabolite Metabolic Disease
    Glycogen, Oysters is a glycolytic intermediates and high-energy phosphates that can serve as a form of energy storage in humans, animals, fungi, and bacteria.
    Glycogen, Oysters
  • HY-113511B

    Biochemical Assay Reagents Others
    Glycogen, from rabbit liver, ≥85% is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    Glycogen, from rabbit liver, ≥85%
  • HY-113511C

    Biochemical Assay Reagents Others
    Glycogen, from bovine liver, ≥85% is a biochemical reagent that can be used as a biomaterial or organic compound for life science related research .
    Glycogen, from bovine liver, ≥85%
  • HY-P1113A

    GSK-3 Others
    Phospho-Glycogen Synthase Peptide-2 (substrate) is peptide substrate for glycogen synthase kinase-3 (GSK-3) and can be used for affinity purification of protein-serine kinases .
    Phospho-Glycogen Synthase Peptide-2(substrate) TFA
  • HY-131062

    Others Metabolic Disease
    yGsy2p-IN-1 is a potent inhibitor for yeast glycogen synthase 2 (yGsy2p). yGsy2p-IN-1 is a competitive human glycogen synthase 1 (hGYS1) inhibitor with an IC50 of 2.75 µM and a Ki of 1.31 µM for wild-type hGYS1. yGsy2p-IN-H23 a pyrazole inhibitor, is used for glycogen storage diseases (GSDs) .
    yGsy2p-IN-1
  • HY-128029

    Others Metabolic Disease
    Glycogen phosphorylase-IN-1 (Compound 42) is an inhibitor for human liver glycogen phosphorylase (hlGPa) and hepatocyte glycogen-derived glucose production with IC50s of 53 and 380 nM, respectively. Glycogen phosphorylase-IN-1 reveals efficacy towards type 2 diabetes .
    Glycogen phosphorylase-IN-1
  • HY-E70116

    glycogen α-1,6-glucanohydrolase

    Others Others
    Isoamylase (Glycogen α-1,6-glucanohydrolase) catalyzes the hydrolysis of α-1,6-glycosidic linkages in glycogen, amylopectin and α/β-limit dextrins .
    Isoamylase
  • HY-P1113

    GSK-3 Others
    Phospho-Glycogen Synthase Peptide-2 (substrate) is peptide substrate for glycogen synthase kinase-3 (GSK-3) and can be used for affinity purification of protein-serine kinases .
    Phospho-Glycogen Synthase Peptide-2(substrate)
  • HY-P3741

    PKC Neurological Disease
    [Ala9,10, Lys11,12] Glycogen Synthase (1-12) is a selective substrate for phosphorylation by protein kinase C (PKC). [Ala9,10, Lys11,12] Glycogen Synthase (1-12) can be used to determine the activity of protein kinase C .
    [Ala9,10, Lys11,12] Glycogen Synthase (1-12)
  • HY-157646

    GYS1-IN-2

    Others Metabolic Disease
    MZ-101 (GYS1-IN-2) is an orally active, potent and selective small-molecule glycogen synthase 1 (GYS1) inhibitor with with an IC50 value of 0.041 µM. MZ-101 reduces glycogen concentrations in cells and in mice. MZ-101 can used to study GYS1 -mediated Pompe disease and other glycogen storage diseases .
    MZ-101
  • HY-P2558

    GSK-3 Others
    GSK3 Substrate, α, β subunit is peptide substrate for glycogen synthase kinase-3 (GSK-3) and can be used to measure GSK-3 activity .
    GSK3 Substrate, α, β subunit
  • HY-P4060

    Neuropeptide Y Receptor Metabolic Disease Endocrinology
    Pancreatic polypeptide is a peptide secreted by the endocrine PP cells of the pancreas that regulates pancreatic secretory activity and also affects hepatic glycogen stores and gastrointestinal secretion .
    Pancreatic polypeptide
  • HY-156032

    GSK-3 Neurological Disease
    PIMPC is a compound with antioxidant and metal-chelating properties. PIMPC is a novel inhibitor of glycogen synthase kinase 3 (GSK-3). PIMPC has potential anti-Alzheimer's disease effect .
    PIMPC
  • HY-P99803

    VAL-1221

    Glucosidase Others
    Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research .
    Clervonafusp alfa
  • HY-131177

    Others Metabolic Disease
    yGsy2p-IN-H23 is a potent and first-in-class inhibitor for yeast glycogen synthase 2 (yGsy2p) with an IC50 of 875 µM for human glycogen synthase 1 (hGYS1). yGsy2p-IN-H23 bounds within the uridine diphosphate glucose binding pocket of yGsy2p. yGsy2p-IN-H23 is used for the research of glycogen storage diseases (GSDs) .
    yGsy2p-IN-H23
  • HY-108614

    Others Metabolic Disease
    GPi688 is a potent and orally active glycogen phosphorylase (GPa) inhibitor with IC50s of 19 nM, 61 nM and 12 nM for human liver GPa, rat liver GPa and human skeletal muscle GPa, respectively . GPi688 can inhibit glucagons-mediated glucose output in rat primary hepatocytes. GPi688 can be used for researching glucagon-mediated hyperglycaemia .
    GPi688
  • HY-12074

    GSK-3 Metabolic Disease
    Cazpaullone is a glycogen synthase kinase-3 (GSK-3) inhibitor. Cazpaullone can activate pancreatic beta cell protection and replication. Cazpaullone can be used for the research of diabetes .
    Cazpaullone
  • HY-141480

    GSK-3 Apoptosis Cancer
    GSK-3β inhibitor 3 is a potent, selective, irreversible and covalent inhibitor of Glycogen Synthase Kinase 3β (GSK-3β), with an IC50 of 6.6 μM. GSK-3β inhibitor 3 can be used for the research of acute promyelocytic leukemia .
    GSK-3β inhibitor 3
  • HY-P4685

    Angiotensin Receptor Metabolic Disease
    (Sar1,Ile4,8)-Angiotensin II is a functionally selective angiotensin II type 1 receptor (AT1R) agonist. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated insulin receptor (IR) signaling and glycogen synthesis. (Sar1,Ile4,8)-Angiotensin II potentiates insulin-stimulated phosphorylation of Akt and GSK3α/β .
    (Sar1,Ile4,8)-Angiotensin II
  • HY-108615

    GPi 819

    Others Endocrinology
    CP 316819 is a potent glycogen phosphorylase (GPase) inhibitor with antihyperglycemic effect (IC50 values are 17 and 34 nM against human skeletal muscle glycogen phosphorylase (huSMGPa) and liver glycogen phosphorylase (huLGPa) respectively).CP 316819 causes glycogen accumulation under normoglycemic conditions but permits glycogen utilization when glucose concentrations are low.CP-316819 prevents neuronal cell death and maintains brain electrical currents .
    CP-316819
  • HY-19396
    Ingliforib
    1 Publications Verification

    CP 368296; GPi 296

    Others Cardiovascular Disease
    Ingliforib (CP 368296) is a glycogen phosphorylase inhibitor, with IC50s of 52, 352 and 150 nM for liver, muscle and brain glycogen phosphorylase, and has cardioprotective activity.
    Ingliforib
  • HY-13525
    CP-91149
    4 Publications Verification

    Others Metabolic Disease Cancer
    CP-91149 is a GP (glycogen phosphorylase) inhibitor. CP-91149 promotes glycogen resynthesis, but not its overaccumulation. CP-91149 has the potential for Type II (insulin-dependent) diabetes study .
    CP-91149
  • HY-100320

    Others Metabolic Disease
    AVE5688 is an inhibitor of glycogen phosphorylase (GP), with IC50s of 430 nM and 915 nM and Kds of 170 nM and 530 nM for rabbit muscle glycogen phosphorylase (rmGPb and rmGPa, respectively); AVE5688 can be used for the research of type 2 diabetes.
    AVE5688
  • HY-N1932

    Others Metabolic Disease
    Bayogenin is an alfalfa saponin, shows moderate potency of glycogen phosphorylase inhibition .
    Bayogenin
  • HY-P0315
    Crosstide
    1 Publications Verification

    Akt Others
    Crosstide is a peptide analog of glycogen synthase kinase α/β fusion protein sequence which is a substrate for Akt.
    Crosstide
  • HY-107815

    GSK-3 Neurological Disease
    CHIR 98024 (Compound L) is a glycogen synthase kinase 3 (GSK3) inhibitor with an EC50 of 0.2566 μM .
    CHIR 98024
  • HY-Q48328

    GSK-3 Metabolic Disease
    GSK3-IN-1 (compound 11) is a GSK-3 inhibitor with an IC50 value of 12 μM. GSK3-IN-1 can be used in the research of diabetes .
    GSK3-IN-1
  • HY-15424
    5-Iodotubercidin
    5+ Cited Publications

    NSC 113939; 5-ITu

    Adenosine Kinase Cancer
    5-Iodotubercidin (NSC 113939), an ATP mimetic, is a potent adenosine kinase inhibitor with an IC50 of 26 nM. 5-Iodotubercidin (NSC 113939) initiates glycogen synthesis in isolated hepatocytes by causing inactivation of phosphorylase and activation of glycogen synthase. 5-Iodotubercidin (NSC 113939) also inhibits CK1, insulin receptor tyrosine kinase, phosphorylase kinase, PKA, CK2, PKC and Haspin .
    5-Iodotubercidin
  • HY-108828

    rhGAA

    Others Others
    Alglucosidase alfa is a hydrolytic lysosomal glycogen-specific recombinant human α-glucosidase product. Alglucosidase alfa can be used for Pompe disease research .
    Alglucosidase alfa
  • HY-E70183

    EC:3.2.1.20; GAA

    Biochemical Assay Reagents Others
    Lysosomal α-Glucosidase (EC:3.2.1.20) is a γ-amylase with specificity for glycogen and several natural and synthetic oligoglucosides .
    Lysosomal α-Glucosidase
  • HY-120872

    Others Metabolic Disease
    AJS1669 free acid is a potent and orally available glycogen synthase (GS) activator. AJS1669 improves glucose metabolism and reduces body fat mass in mice[1].
    AJS1669 free acid
  • HY-W145493

    Tetraglycol; Poly(ethylene glycol) tetrahydrofurfuryl ether

    Biochemical Assay Reagents Others
    Poly(ethylene glycol) tetrahydrofurfuryl ether is liquid glycogen can be easily transformed into a gel system with excellent elasticity, so it can be used as a medium for dissolving water-insoluble agents.
    Glycofurol
  • HY-P2857A

    Others Others
    Glucoamylase, Rhizopus sp. hydrolyzes α-1,4 and α-1,6 glucosidic bonds in starch and similar substrates, and releases β-glucose molecules primarily from the non-reducing end. Glucoamylase, Rhizopus sp. participates in glycogen metabolism, and is related to glycogen storage disease type II. Glucoamylase, Rhizopus sp. converses starch to glucose, which can be used in industrial production of high fructose syrup, alcohol, and other fermented products .
    Glucoamylase, Rhizopus sp.
  • HY-121262

    Others Others
    Bisabolene is a compound that can be synthesized by engineered bacteria. Bisabolene can be synthesized by heterologous expression of related genes in cyanobacteria. Its production and changes in related metabolites were studied in glycogen-deficient mutants.
    Bisabolene
  • HY-139409

    Others Metabolic Disease
    2-Deoxy-D-glucose 6-phosphate is an intermediate of 2-deoxy-D-glucose (2-DG) . 2-Deoxy-D-glucose is incorporated into glycogen .
    2-Deoxy-D-glucose 6-phosphate
  • HY-59090
    1-Azakenpaullone
    3 Publications Verification

    1-Akp

    GSK-3 Neurological Disease Metabolic Disease
    1-Azakenpaullone (1-Akp) is a highly selective and ATP-competitive inhibitor of glycogen synthase kinase-3 β (GSK-3β), with an IC50 value of 18 nM .
    1-Azakenpaullone
  • HY-131482

    Liposome Others
    PtdIns-(3)-P1(1,2-dioctanoyl) sodium (compound 1b) is a glycogen phosphate that plays a key role in eukaryotic membrane trafficking and agonist-activated intracellular signaling .
    PtdIns-(3)-P1(1,2-dioctanoyl) sodium
  • HY-P1473

    Amylin (8-37) (mouse, rat)

    Amylin Receptor Metabolic Disease
    Amylin (8-37), rat is a truncated analog of native Amylin that selectively inhibits insulin-related glucose uptake and glycogen deposition in muscle tissue. Amylin (8-37), rat is a weak amylin receptor (AMY) antagonist.
    Amylin (8-37), rat
  • HY-126201

    GSK-3 Neurological Disease
    GSK-3 inhibitor 7 (compound 22) is a glycogen synthase kinase-3 (GSK-3) inhibitor. GSK-3 inhibitor 7 can be used in nervous system research .
    GSK-3 inhibitor 7
  • HY-126144
    GSK-3β inhibitor 1
    3 Publications Verification

    GSK-3 Metabolic Disease
    GSK-3β inhibitor 1 (compound 3a) is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy, with an IC50 of 4.9 nM .
    GSK-3β inhibitor 1
  • HY-113585

    Others Others
    1,4-Dideoxy-1,4-imino-D-arabinitol hydrochloride is a naturally occurring pyrrolidine alkaloid that acts as an inhibitor of glycogen phosphorylase and α-glucosidases, and is sourced from Arachniodes standishii and Angylocalyx boutiqueanus.
    1,4-Dideoxy-1,4-imino-D-arabinitol hydrochloride
  • HY-16294
    LY2090314
    10+ Cited Publications

    GSK-3 Cancer
    LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50 values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.
    LY2090314
  • HY-107532

    NN-DNJ; Nonyl-DNJ

    Glucosidase Metabolic Disease
    N-Nonyldeoxynojirimycin (NN-DNJ) is a potent inhibitor of alpha-glucosidase and alpha-1,6-glucosidase (IC50s, 0.42, 8.4 μM, respectively), inhibits glycogen breakdown .
    N-Nonyldeoxynojirimycin
  • HY-P1114

    GSK-3 Neurological Disease
    2B-(SP) is a eIF2B-based substrate for glycogen synthase kinase-3 (GSK-3). 2B-(SP) is readily phosphorylated by both the α and β isoforms of GSK-3 .
    2B-(SP)
  • HY-117172

    Others Metabolic Disease
    CP320626 is a potent inhibitor of human liver glycogen phosphorylase (IC50=205 nM). CP320626 reduces blood glucose in diabetic mice without changing plasma insulin levels. CP320626 can be used in the study of type 2 diabetes .
    CP320626
  • HY-11001
    PHA-793887
    4 Publications Verification

    CDK Apoptosis Cancer
    PHA-793887 is a potent, ATP-competitive CDK inhibitor, can inhibit Cdk2, Cdk1, Cdk4, and Cdk9 with IC50s of 8 nM, 60 nM, 62 nM and 138 nM, respectively, and also inhibits glycogen synthase kinase 3β with an IC50 of 79 nM.
    PHA-793887
  • HY-111926

    Others Metabolic Disease
    N6-Methyladenosine 5'-monophosphate disodium salt is an activator of glycogen phosphorylase b, with a Ka value of 22 µM . N6-Methyladenosine 5'-monophosphate disodium salt is a non-competitive rat adenylate kinase II inhibitor .
    N6-Methyladenosine 5'-monophosphate disodium salt
  • HY-P1114A

    GSK-3 Cancer
    2B-(SP) TFA is a eIF2B-based substrate for glycogen synthase kinase-3 (GSK-3). 2B-(SP) TFA is readily phosphorylated by both the α and β isoforms of GSK-3 .
    2B-(SP) (TFA)
  • HY-148132

    GSK-3 Neurological Disease
    GSK-3β inhibitor 11 (compound 21) is a glycogen synthase kinase-3β (GSK-3β) inhibitor (IC50=10.02 μM). GSK-3β inhibitor 11 can be used in neurodegenerative disease research .
    GSK-3β inhibitor 11

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: